Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part I

References

• http://statbel.fgov.be/nl/statistieken/cijfers/bevolking/sterfte_leven/tafels/
   Google Scholar
• Dibonaventura MD, Chandran A, Hsu MA, Bushmakin A. Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom. Int J Womens Health 2012;5:261–9
   Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Pricipal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Burger HG, Maclennan AH, Huang KE, Castelo-Branco C. Evidence-based assessment of the impact of the WHI on women's health. Climacteric 2012;15:381–7
   Google Scholar
• Gompel A, Santen RJ. Hormone therapy and breast cancer risk 10 years after the WHI. Climacteric 2012;15:241–9
   PubMed Web of Science ®Google Scholar
• Sood R, Faubion SS, Kuhle CL, Thiele JM, Shuster LT. Prescribing menopausal hormone therapy: an evidence-base approach. Int J Womens Health 2014;6:47–57
   PubMedGoogle Scholar
• Comhaire FH, Depypere HT. Hormones, herbal preparations and nutriceuticals for a better life after the menopause: part II. Climacteric 2015;18: 364–71
   PubMed Web of Science ®Google Scholar
• Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47
   PubMedGoogle Scholar
• Conard J. Modifications of the hemostatic balance during estrogen treatments: menopause and its treatment. Therapie 1999;54:363–7
   PubMedGoogle Scholar
• Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006;17:1726–33
   PubMed Web of Science ®Google Scholar
• Palacios S, Christiansen C, Sànchez Borrego R, et al. Recommendations on the management of fragility fracture risk in women younger than 70 years. Gynecol Endocrinol 2012;28:770–86
   PubMed Web of Science ®Google Scholar
• Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012;7,CD002143
   Google Scholar
• Gambacciani M. HRT misuse and the osteoporosis epidemic. Climacteric 2012;15:10–11
   PubMed Web of Science ®Google Scholar
• Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet 2014;383:146–55
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Kaufman JM, Palacios S, Siverman S, et al. An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®. Osteoporos Int 2013; 24:2561–9
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010; 362:686–96
   PubMed Web of Science ®Google Scholar
• Pazianas M, Epstein S, Zaidi M. Evaluating the antifracture efficacy of bisphosphonates. Rev Recent Clin Trials 2009;4:122–30
   PubMedGoogle Scholar
• Cummings SR, San Martin J, McClung M, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;36:756–65
   Google Scholar
• Comhaire F, Vandeweghe M, Vermeulen A. Vascular incidents and oral contraceptives, arterial versus venous thromboembolism: a statistical study. Contraception 1971;3:301–5
   Web of Science ®Google Scholar
• ESC/EAS. Guidelines for the management of dyslipidaemias. Eur Heart J 2011;32:1769–818
   PubMed Web of Science ®Google Scholar
• Kawecka-Jaszcz K, Czarnecka D, Olszanecka A, et al. The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens 2002;16:509–16
   PubMed Web of Science ®Google Scholar
• Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996;87:6–12
   PubMed Web of Science ®Google Scholar
• Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
   PubMed Web of Science ®Google Scholar
• Chu MC, Cushman M, Solomon R, Lobo RA. Metabolic syndrome in postmenopausal women: the influence of oral or transdermal estradiol on inflammation and coagulation markers. Am J Obstet Gynecol 2008;199:526.e1–7
   PubMedGoogle Scholar
• Vehkavaara S, Silveira A, Hakala-Ala-Pietilä T, et al. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 2001;85:619–25
   PubMed Web of Science ®Google Scholar
• Stephenson K, Neuenschwander PF, Kurdowska AK. The effects of compounded biological transdermal hormone replacement therapy on hemostatic, inflammatory, inmune factors; cardiovascular biomarkers; quality-of-life measures, and health outcomes in perimenopausal and postmenopausal women. Int J Pharm Comp 2013;17:74–85
   PubMedGoogle Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–14
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Cheng J, Thabane L, Buckley N, Salpeter E. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;122:1016–22
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933–41
   PubMed Web of Science ®Google Scholar
• Schierbeck L, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012; 345:e6409
   PubMed Web of Science ®Google Scholar
• Bretler DM, Hansen PR, Lindhardsen J, et al. Hormone replacement therapy and risk of new-onset atrial fibrillation after myocardial infarction – a nationwide cohort study. PLoSOne 2012;7:e51580
   Google Scholar
• Rockman CB, Maldonado TS, Jacobowitz GR, et al. Hormone replacement therapy is associated with a decreased prevalence of peripheral arterial disease in postmenopausal women. Ann Vasc Surg 2012;26:411–18
   PubMed Web of Science ®Google Scholar
• Ruszkowska B, Gadomska G, Bielis L, et al. Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy. J Zheijang Univ Sci B 2011;12:12–17
   PubMed Web of Science ®Google Scholar
• Wakatsuki A, Ikenoue N, Shinohara K, et al. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women. Arteriosclerosis 2003;23:1948–9
   Google Scholar
• Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005;293:935–48
   PubMed Web of Science ®Google Scholar
• Robinson D, Cardozo L. Estrogens and the lower urinary tract. Neurourol Urodyn 2011;30:754–7
   PubMed Web of Science ®Google Scholar
• Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;(4):CD001500
   PubMed Web of Science ®Google Scholar
• Grady D, Brown J, Vittinghoff E, Applegate W, Varner E, Snyder T, for the HERS research group. Postmenopausal hormones and incontinence: the Heart and Estrogen/progestin Replacement Study. Obstet Gynecol 2001;97:116–20
   PubMed Web of Science ®Google Scholar
• Cody JD, Jacobs ML, Richardson K, et al. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012;10:CD 001405
   Google Scholar
• Lüthje P, Brauner H, Ramos NL, et al. Estrogen supports urothelial defense mechanisms. Sci Transl Med 2013;5:190ra80
   Google Scholar
• Lammerink EA, de Bock GH, Schröder CP, Mourits MJ. The management of menopausal symptoms in breast cancer survivors: case-based approach. Maturitas 2012;73:265–8
   PubMed Web of Science ®Google Scholar
• Chlebowski RT, Manson JE, Anderson GL, et al. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst 2013;17:526–35
   Google Scholar
• Chen WY. Postmenopausal hormone therapy and breast cancer risk: current status and unanswered questions. Endocrinol Metab Clin North Am 2011;40:509–18
   PubMed Web of Science ®Google Scholar
• Kroenke CH, Chen WY, Rosner B, Holmes MD.Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 2005;23:1370–8
   PubMed Web of Science ®Google Scholar
• Amadou A, Hainaut P, Romieu I. Role of obesity in the risk of breast cancer: lessons from anthropometry. J Oncol 2013;2013:906495
   PubMedGoogle Scholar
• Fournier A, Fabre A, Mesrine S, et al. Use of different postmenopausal hormone therapies and risk of histology- and hormone receptor-defined invasive breast cancer. J Clin Oncol 2008;26:1260–8
   PubMed Web of Science ®Google Scholar
• Lidegaard O, Løkkegaard E, Helms A; Danish Sex Hormone Register Study. Hormone therapy and breast cancer. 2011 www.slideserve.com/…/Danish-sex-Hormone-Register-Study-DaHoRS
   Google Scholar
• Shoupe D. Individualizing hormone therapy to minimize risk: accurate assessment of risks and benefits. Womens Health 2011;7:475–85
   Google Scholar
• Opatrny L, Dell’Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. BJOG 2008;115:169–75
   PubMed Web of Science ®Google Scholar
• Curtis KM, Marchbanks PA, Peterson HB. Neoplasia with use of intrauterine devices. Contraception 2007;75(6 Suppl):S60–9
   PubMed Web of Science ®Google Scholar
• Myytinen HK, Dyba T, Ylikorkala O, Pukkala EI. A case-control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carriers a risk as well. Int J Cancer 2010;15:483–9
   Google Scholar
• Dinger J, Bardenheuer K, Minh TD. Levonorgestrel-releasing and copper intrauterine devices and the risk of breast cancer. Contraception 2011;83:211–17
   PubMed Web of Science ®Google Scholar
• Wong AW, Chan SS, Yeo W, Yu MY, Tam WH. Prophylactic use of levonorgestrel-releasing intrauterine system in women with breast cancer treated with tamoxifen: a randomized controlled trial. Obstet Gynecol 2013;121:943–50
   PubMed Web of Science ®Google Scholar
• Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2012;8:CD 000402
   Google Scholar
• Crandall CJ. Estrogen replacement therapy and colon cancer: a clinical review. J Womens Health Gend Based Med 1999;8: 1155–66
   PubMedGoogle Scholar
• Wu AH, Siegmund KD, Long TI, et al. Hormone therapy, DNA methylation and colon cancer. Carcinogenesis 2010;31:1060–7
   PubMed Web of Science ®Google Scholar
• Slatore CG, Chien JW, Au dh, et al. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 2010;28:1540–6
   PubMed Web of Science ®Google Scholar
• Chen KY, Hsiao CF, Chang GC, et al. Hormone replacement therapy and lung cancer risk in Chinese. Cancer 2007;110:1768–75
   PubMed Web of Science ®Google Scholar
• Ayeni O, Robinson A. Hormone replacement therapy and the outcomes for women with non-small-cell lung cancer: can an association be confirmed? Curr Oncol 2009;16:21–5
   PubMedGoogle Scholar
• Chen KY, Hsiao CF, Chang GC, et al. EGFR polymorphisms, hormone replacement therapy and lung adenocarcinoma risk: analysis from a genome-wide association study in never-smoking women. Carcinogenesis 2013;34:612–19
   PubMed Web of Science ®Google Scholar
• Hart AR, Luben R, Welch A, Bingham S, Khaw KT. Hormone replacement therapy and symptomatic gallstones – a prospective population study in the EPIC-Norfolk cohort. Digestion 2008; 77:4–9
   PubMed Web of Science ®Google Scholar
• Uhler ML, Marks JW, Voigt BJ, Judd HL. Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women. J Clin Endocriol Metab 1998;83:410–14
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Cappagli B, Ciaponi M, et al. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women. Maturitas 2008;59:2–6
   PubMed Web of Science ®Google Scholar
• Tuppurainen M, Härmä K, Komulainen M, et al. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up. Maturitas 2010;66:426–30
   Google Scholar
• Hodis HN, Mack WJ. Coronary heart disease and hormone replacement therapy after the menopause. Climacteric 2009; 12(Suppl 1):71–5
   PubMedGoogle Scholar
• Kika G, Izumi S, Mori A, et al. Beneficial aspect of oral estriol as hormone replacement therapy: consideration on bone and lipid metabolism. Tokai J Exp Clin Med 2009;34:92–8
   PubMedGoogle Scholar
• Sites CK, Brochu M, Tchernof A, Poehlman ET. Relationship between hormone replacement therapy use with body fat distribution and insulin sensitivity in obese postmenopausal women. Metabolism 2001;50:835–40
   PubMed Web of Science ®Google Scholar
• Sörensen MB, Rosenfalck AM, Höjgaard L, Ottensen B. Obesity and sarcopenia after menopause are reversed by sex hormone replacement therapy. Obes Res 2001;9:622–6
   PubMedGoogle Scholar
• Ferrara A, Karter AJ, Ackerson LM, et al. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes: The Northern California Kaiser Permanente Diabetes Registry. Diabetes Care 2001;24:1144–50
   PubMed Web of Science ®Google Scholar
• Welton AJ, Vickers MR, Kim J, et al.; WISDOM team. Health related quality of life after combined hormone replacement therapy: randomized controlled trial. BMJ 2008;337:a1190
   PubMed Web of Science ®Google Scholar
• Gast MJ, Freedman MA, Vieweg AJ, et al. A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. Menopause 2009;16:247–56
   PubMed Web of Science ®Google Scholar
• Lethaby A, Hogervorst E, Richards M, et al. Hormone replacement therapy for cognitive function in postmenopausal women. Cochrane Database Syst Rev 2008;(1):CD003122
   Web of Science ®Google Scholar
• Ross LA, Alder EM, Cawood EH, et al. Psychological effects of hormone replacement therapy: a comparison of tibolone and sequential estrogen therapy. J Psychosom Obstet Gynaecol 1999;20;88–96
   PubMed Web of Science ®Google Scholar
• Patacchioli FR, Simeoni S, Monnazzi P, Pace M, Capri O, Perrone G. Menopause, mild psychological stress and salivary cortisol: influence of long-term hormone replacement therapy (HRT). Maturitas 2006;55:150–5
   PubMed Web of Science ®Google Scholar
• Katz-Bearnot S. Menopause, depression, and loss of sexual desire: a psychodynamic contribution. J Am Acad Psychoanal Dyn Psychiatry 2010;38:99–116
   PubMedGoogle Scholar
• Polo-Kantola P, Erkkola R. Sleep and the menopause. J Br Menopause Soc 2004;10:145–50
   PubMedGoogle Scholar
• Magliano M. Menopausal arthralgia: Fact or fiction. Maturitas 2010;67:29–33
   PubMed Web of Science ®Google Scholar
• Sator PG, Sator MO, Schmidt JB, et al. A prospective, randomized, double-blind, placebo-controlled study on the influence of hormone replacement therapy on skin aging in postmenopausal women. Climacteric 2007;10:320–34
   PubMed Web of Science ®Google Scholar
• Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMs. Clin Interv Aging 2007;2: 283–97
   PubMed Web of Science ®Google Scholar
• Guashino S; Grimaldi E, Satore A, et al. Visual function in menopause: the role of hormone replacement therapy. Menopause 2003;10:53–7
   PubMed Web of Science ®Google Scholar
• Noreen F, Roosli M, Gaj P, et al. Modulation of age- and cancer associated DNA methylation change in healthy colon by aspirin and lifestyle. J Natl Cancer Inst 2014;106(7). Pii: dju 161
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Boulman N, Leiba R, et al. High C-reactive protein levels are associated with oral hormonal menopausal therapy but not with intrauterine levonorgestrel and transdermal estradiol. Scand J Lab Invest 2007;67:257–63
   PubMed Web of Science ®Google Scholar
• Baulieu EE. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 1996;81:3147–51
   PubMed Web of Science ®Google Scholar
• Baulieu EE, Thomas G, Legrain S, et al. Dehydroepiandrosterone (DHEA), DHEA sulphate, and aging: contribution of the DHEAage Study to a sociobiomedical issue. Proc Natl Acad Sci USA 2000;97:4279–84
   PubMed Web of Science ®Google Scholar
• Percheron G, Hogrel JY, Denot-Ledunois S, et al. Effect of 1-year oral administration of dehydroepiandrosterone to 60- to 80-year-old individuals on muscle function and cross-sectional area: a double-blind placebo-controlled trial. Arch Intern Med 2003; 163:720–7
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Stomati M, Valentino V, et al. Effect of 1-year, low-dose DHEA therapy on climacteric symptoms and female sexuality. Climacteric 2011;14:661–8
   PubMed Web of Science ®Google Scholar
• Panjari M, Bell RJ, Jane F, et al. A randomized trial of oral DHEA treatment for sexual function, well-being, and menopausal symptoms in postmenopausal women with low libido. J Sex Med 2009;6:2579–90
   PubMed Web of Science ®Google Scholar
• López-Marure R, Contreras PG, Dillon JS. Effects of dehydroepiandrosterone on proliferation, migration, and death of breast cancer cells. Eur J Pharmacol 2011;660:268–74
   PubMed Web of Science ®Google Scholar
• Gomez-Santos C, Hernandez-Morante JJ, Tébar FJ, Granero E, Garaulet M. Differential effect of dehydroepiandrosterone- sulphate on metabolic syndrome features in pre- and postmenopausal obese women. Clin Endocinol (Oxf) 2012;77:548–54
   PubMed Web of Science ®Google Scholar
• Weiss EP, Villareal DT, Fontana L, Han DH, Holloszy JO. Dehydroepiandrosterone (DHEA) replacement decreases insulin resistance and lowers inflammatory cytokines in aging humans. Aging 2011;3:533–42
   PubMedGoogle Scholar
• Savineau JP, Marthan R, Dumas de la Roque E. Role of DHEA in cardiovascular diseases. Biochem Pharmacol 2013; 85:718–26
   PubMed Web of Science ®Google Scholar
• Weiss EP, Villareal DT, Ehsani AA, Fpntana L, Holloszy JO. Dehydroepiandrosterone replacement therapy in older adults improves indices of arterial stiffness. Aging Cell 2012;11:876–84
   PubMed Web of Science ®Google Scholar
• Goel RM, Cappola AR. Dehydroepiandrosterone sulfate and postmenopausal women. Curr Opin Endrocrinol Diabetes Obes 2011;18:171
   PubMed Web of Science ®Google Scholar